Suggested remit: To appraise the clinical and cost effectiveness of ciltacabtagene autoleucel within its marketing authorisation for relapsed or refractory multiple myeloma.
 
Status In progress
Decision Selected
Process STA 2018
ID number 3816

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Stakeholders

Companies sponsors Janssen (ciltacabtagene autoleucel)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Leukaemia Care
  Myeloma UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Myeloma Forum
Comparator companies Celgene (lenalidomide, pomalidomide) (confidentiality agreement signed, participating)
  Janssen-Cilag (bortezomib) (confidentiality agreement signed, participating)
  Advanz pharma (dexamethasone) (confidentiality agreement not signed, not participating)
  Amgen (carfilzomib) (confidentiality agreement not signed, not participating)
  Aspen (dexamethasone) (confidentiality agreement not signed, not participating)
  Aspire pharma (bortezomib, dexamethasone) (confidentiality agreement not signed, not participating)
  Consilient health (dexamethasone) (confidentiality agreement not signed, not participating)
  Dr Reddy’s laboratories (bortezomib) (confidentiality agreement not signed, not participating)
  Glenmark pharmaceuricals (dexamethasone) (confidentiality agreement not signed, not participating)
  Martindale pharma (dexamethasone) (confidentiality agreement not signed, not participating)
  Mylan (bortezomib) (confidentiality agreement not signed, not participating)
  Novartis pharmaceuticals (panobinostat) (confidentiality agreement not signed, not participating)
  Rosemont pharmaceuticals limited (dexamethasone) (confidentiality agreement not signed, not participating)
  Teva (dexamethasone) (confidentiality agreement not signed, not participating)
  Thornton & Ross (bortezomib) (confidentiality agreement not signed, not participating)
  Zentiva (bortezomib) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
09 November 2021 Committee meeting: 1
12 March 2021 Invitation to participate
14 January 2021 - 11 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 March 2020 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual